Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Can Philips AI Spectral CT Outpace Costly Photon Counting?
Infrastructure & Management Can Philips AI Spectral CT Outpace Costly Photon Counting?

Hospital radiology leaders faced a stark calculation today: how to deliver sharper answers faster without sinking capital budgets into technology that slows throughput or requires specialized workflows, all while keeping radiation dose under control and staff time predictable across stacked

GLP-1 Care Goes Mobile: Apps Become the Clinic in 2026
Digital Health GLP-1 Care Goes Mobile: Apps Become the Clinic in 2026

Inbox pings have replaced waiting room calls as GLP-1 therapy moved from a maze of appointments and approvals into an app-mediated workflow that compresses intake, prescribing, and delivery into a single, guided lane. In minutes, adaptive questionnaires collect medical history, contraindications,

Can the FTC’s USAP Deal Rein in Private Equity Roll-Ups?
Regulatory & Compliance Can the FTC’s USAP Deal Rein in Private Equity Roll-Ups?

James Maitland has spent years in the trenches of healthcare antitrust and physician-practice M&A, advising on how roll-ups change bargaining dynamics, how remedies land in the real world, and how to translate legal settlements into better patient access and sustainable hospital operations. In this

Administrators Strengthen Resilience During Health Crises
Digital Health Administrators Strengthen Resilience During Health Crises

The recorded surge of measles cases in Utah throughout early April served as a stark reminder that the efficacy of a medical response is fundamentally tied to the quality of administrative infrastructure rather than clinical expertise alone. While public health messaging typically emphasizes

Can Mining Metals Lead the Way in Modern Cancer Care?
Digital Health Can Mining Metals Lead the Way in Modern Cancer Care?

The global mining industry is currently undergoing a radical transformation as traditional extractive practices converge with the frontier of precision oncology to redefine the value of precious metals. This unprecedented shift is most visible in the strategic collaboration between the mining giant

Can Insurers Challenge No Surprises Act Awards in Court?
Infrastructure & Management Can Insurers Challenge No Surprises Act Awards in Court?

Understanding the Judicial Shield Around Arbitration Awards The escalating financial stakes in the multi-billion dollar healthcare reimbursement market have reached a boiling point as federal courts begin to cement the finality of independent arbitration awards. This development marks a significant

Are Medical Scans Increasing Your Long-Term Cancer Risk?
Digital Health Are Medical Scans Increasing Your Long-Term Cancer Risk?

In an environment where diagnostic speed often dictates the outcome of critical medical emergencies, the pervasive use of advanced imaging technology has reached unprecedented levels across the modern healthcare landscape. Recent data reveals that in 2023 alone, the United States healthcare system

How Will IoT and Connectivity Reshape Modern Healthcare?
Digital Health How Will IoT and Connectivity Reshape Modern Healthcare?

The paradigm shift toward a decentralized healthcare model is currently redefining the boundaries between clinical facilities and patient living spaces through the pervasive application of the Internet of Things. Modern medicine is no longer confined to the four walls of a hospital or the periodic

How Will the FDA’s New Peptide Policy Reshape Public Health?
Regulatory & Compliance How Will the FDA’s New Peptide Policy Reshape Public Health?

James Maitland is a distinguished expert in the field of health policy and pharmaceutical regulation, specializing in the intersection of biotechnology and patient safety. With years of experience navigating the complexities of the FDA’s regulatory frameworks, he provides a unique perspective on

Are Your Store-Brand Eye Drops Part of a Massive Recall?
Infrastructure & Management Are Your Store-Brand Eye Drops Part of a Massive Recall?

When a routine visit to the local pharmacy results in the purchase of a common healthcare staple, few consumers anticipate that their trusted lubricating eye drops might harbor invisible risks due to manufacturing failures. The recent announcement by the Food and Drug Administration regarding the

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later